Physician profile
Barbara Oland
NPI 1780199554
$4,512.85
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,226 · 2022: $1,481 · 2023: $1,792 · 2024: $13.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,573.36 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,340.67 | 2021-2024 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $391.89 | 2021-2023 | Stelara, Simponi, Remicade |
| Qol Medical, LLC | $388.93 | 2021-2023 | Sucraid |
| Gilead Sciences, INC. | $187.87 | 2021-2023 | |
| Celgene Corporation | $117.22 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $104.93 | 2021-2022 | |
| Amgen INC. | $65.47 | 2022-2023 | Avsola |
| Takeda Pharmaceuticals U.S.A., INC. | $61.11 | 2021 | |
| Merck Sharp & Dohme LLC | $53.99 | 2023 | Dificid |
| Pfizer INC. | $48.05 | 2021 | |
| Ardelyx, INC. | $47.65 | 2023 | Ibsrela |
| Daiichi Sankyo INC. | $39.03 | 2021 | |
| Ferring Pharmaceuticals INC. | $38.04 | 2023 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.89 | 2023 | Cyltezo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $19.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Oland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.